Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Cerebrovascular Accident, Hemiparesis
Interventions: Ropinirole (+ physical therapy), (vs.) Placebo + physical therapy; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: Alzheimer's Disease
Interventions: PF-05212377 (SAM-760), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more

Conditions: Migraine
Interventions: DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C); Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more

Conditions: Healthy
Interventions: SPY002-091, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 68
States / cities: Mobile, Alabama • Pell City, Alabama • Mesa, Arizona + 65 more

Conditions: Infections
Interventions: Azithromycin Pill, Placebo; Drug
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Colton, California

Conditions: Hidradenitis Suppurativa
Interventions: infliximab, Placebo Comparator; Drug
Lead sponsor: Florida Academic Dermatology Centers; Other
Eligibility: 16 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone; Combination Product
Lead sponsor: Hal Chapman; Other
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more

Conditions: Nicotine Dependence, Smoking
Interventions: N-acetylcysteine (NAC), Placebo; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity, Diabetes Mellitus, Non-Insulin-Dependent, Obesity in Diabetes
Interventions: Rimonabant (SR141716); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,045 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Whey Protein Isolate Crossover, Placebo; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 50 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 0 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 37
States / cities: Beverly Hills, California • Palm Springs, California • Sacramento, California + 26 more

Conditions: Coronavirus Infection
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Stem Cell Surveillance
Interventions: Anthocyanin-rich berry extract, Anthocyanin-rich flower/leaf extract, Berry /leaf blend, Placebo; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Rheumatoid Arthritis (RA)
Interventions: Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more

Conditions: Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 232
States / cities: Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Rituximab, Plasmapheresis; Drug · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 1 Year to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 12
States / cities: Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more

Conditions: Healthy
Interventions: Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Alzheimer's Disease
Interventions: Memantine, Placebo; Drug
Lead sponsor: Florida Atlantic University; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib disodium (R935788), Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more

Conditions: Healthy Volunteer
Interventions: aleglitazar, placebo, ibuprofen; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV, HIV Lipodystrophy
Interventions: tesamorelin, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pneumococcal Infection
Interventions: V110, V114, mRNA-1273, Placebo for V110, Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 42
States / cities: North Hollywood, California • Northridge, California • Paramount, California + 38 more

Search by objective public record fields.

Trial of Ropinirole in Motor Recovery After Stroke

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

A Study of SPY002-091 in Healthy Volunteers

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Azithromycin Before Induction

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

N-acetylcysteine for Tobacco Use Disorder

Obese Patients With Type 2 Diabetes

Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals

A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Acute Effects on Stem Cell Surveillance

Methotrexate-Inadequate Response Study

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

Effects of Growth Hormone Releasing Hormone in HIV

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)